secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIODESIX INC (BDSX)
CIK:        0001439725
Form:       8-K
Filed at:   2026-05-04T23:59:59+00:00
Accession:  0001193125-26-203936
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biodesix Q1 revenue $25.6M (+42% YoY); raises FY 2026 revenue guidance to $108-114M
--------------------------------------------------------------------------------

- Total revenue $25.6M, +42% YoY; Diagnostic Testing $22.3M (+37%), Development Services $3.3M (+99%).
- Test volumes up 29% to 17,800; average revenue per test improved on expanded payer coverage and RCM enhancements.
- Gross margin 82% (excl. one-time $0.4M recovery), up 300 bps YoY; net loss $7.8M (improved 30%); Adj. EBITDA loss $4.1M (improved 35%).
- FY 2026 revenue guidance raised to $108-114M (from $106-112M), midpoint implies 25% growth; expects continued Adj. EBITDA improvement.
- Cash $25.6M, up 35% from Dec 2025; includes $16.8M ATM net proceeds, partially offset by Q1 cash outflows.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1439725/000119312526203936/0001193125-26-203936-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1439725/000119312526203936/bdsx-20260504.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-203936

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer